PremiumRatingsAbbVie: Strong Financial Performance and Growth Prospects Drive Positive Analyst Outlook AbbVie price target raised to $250 from $241 at Morgan Stanley AbbVie Reports Strong Q1 2025 Financial Results PremiumThe FlyAbbVie says ‘significant progress’ continues with the pipeline AbbVie raises FY25 revenue view to ~$59.7B from ~$59B, consensus $59.49B AbbVie expects any tariff impact to be in-line with peers PremiumThe FlyNotable companies reporting before tomorrow’s open AbbVie submits BLA to FDA for trenibotulinumtoxinE Is ABBV a Buy, Before Earnings? 
